The successful restoration of bestrophin 1 function in patient-derived RPE confirms 4PBA as a promising therapeutic treatment for bestrophinopathies and validates the data from cell models used in compound screening. This evidence concerns the gene BEST1 and autosomal recessive bestrophinopathy.